Daily Endocrinology Research Analysis
A double-blind phase 3 randomized trial in NEJM shows that once-weekly coadministration of cagrilintide and semaglutide produces large weight loss and glycemic improvements in adults with obesity and type 2 diabetes. A lipidomic signature (notably desmosterol and phosphatidylcholine, plus a multi-lipid panel with ALT) non-invasively distinguished MASH from MASL with high accuracy. Across two national cohorts, higher dietary alpha-linolenic acid intake was associated with lower all-cause and card
Summary
A double-blind phase 3 randomized trial in NEJM shows that once-weekly coadministration of cagrilintide and semaglutide produces large weight loss and glycemic improvements in adults with obesity and type 2 diabetes. A lipidomic signature (notably desmosterol and phosphatidylcholine, plus a multi-lipid panel with ALT) non-invasively distinguished MASH from MASL with high accuracy. Across two national cohorts, higher dietary alpha-linolenic acid intake was associated with lower all-cause and cardiovascular mortality in type 2 diabetes.
Research Themes
- Obesity pharmacotherapy and incretin-based combinations
- Non-invasive diagnostics for MASLD/MASH via lipidomics
- Dietary fatty acids and long-term outcomes in type 2 diabetes
Selected Articles
1. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
In a 68-week, double-blind phase 3 trial (n=1206), once-weekly cagrilintide-semaglutide led to a mean −13.7% weight change vs −3.4% with placebo and markedly higher proportions achieving weight-loss thresholds. Additionally, 73.5% of patients reached HbA1c ≤6.5% vs 15.9% on placebo. Gastrointestinal adverse events were more frequent with CagriSema but were mostly mild to moderate and transient.
Impact: This large, multicountry, double-blind RCT provides robust evidence that dual cagrilintide-semaglutide delivers substantial weight and glycemic benefits in T2D with obesity, potentially redefining pharmacotherapy strategies.
Clinical Implications: CagriSema could become a powerful weekly option for people with T2D and obesity, enabling clinically meaningful weight loss and improved glycemic targets. Clinicians should monitor GI tolerability and consider dose-escalation strategies.
Key Findings
- Mean weight change at 68 weeks: −13.7% with cagrilintide-semaglutide vs −3.4% with placebo (P<0.001).
- Higher proportions achieved ≥5%, ≥10%, ≥15%, and ≥20% weight loss with CagriSema (all P<0.001).
- HbA1c ≤6.5% achieved in 73.5% with CagriSema vs 15.9% with placebo.
- Gastrointestinal adverse events occurred in 72.5% vs 34.4% (mostly mild/moderate, transient).
Methodological Strengths
- Phase 3a, double-blind, randomized, placebo-controlled design across 12 countries
- Intention-to-treat (treatment-policy estimand) analysis with large sample size (n=1206)
Limitations
- Increased gastrointestinal adverse events in the active arm requiring tolerability management
- Duration limited to 68 weeks; no active-comparator arm; industry-funded
Future Directions: Head-to-head comparisons with other anti-obesity agents, long-term cardiometabolic outcomes, and pragmatic studies on adherence and GI tolerability are warranted.
BACKGROUND: Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight management in adults with type 2 diabetes, including those in a subgroup who are undergoing continuous glucose monitoring. METHODS: In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide-semaglutide (2.4 mg each) or placebo, along with lifestyle intervention, for 68 weeks. The two primary end points were the percent change in body weight and the percentage of patients with a weight reduction of at least 5%. Additional end points were changes in glycemic measures and safety assessments. Effect estimates were calculated with the use of the treatment-policy estimand (consistent with the intention-to-treat principle). RESULTS: A tota
2. Non-invasive identification of steatohepatitis in patients with MASLD using a sterol and lipidomic signature.
In a histology-anchored cohort (n=86), serum desmosterol and phosphatidylcholine were higher in MASH than MASL. After excluding lipid-lowering drug users, multiple lipid classes and species increased in MASH. Diagnostic performance was strong: AUROC 0.79 for desmosterol, 0.80 for phosphatidylcholine, and 0.91 for a multi-lipid panel combined with ALT.
Impact: Provides a plausible, blood-based lipidomic signature with high diagnostic accuracy for MASH, addressing a major unmet need for non-invasive alternatives to liver biopsy.
Clinical Implications: If validated externally, a sterol/lipidomic panel (with ALT) could triage MASLD patients for biopsy, enable monitoring, and facilitate patient selection for MASH therapeutics.
Key Findings
- Serum desmosterol and phosphatidylcholine were significantly increased in MASH vs MASL.
- Excluding lipid-lowering drug users, additional lipid classes (e.g., cholesterol esters, LPC, LPE, PE) and species were elevated in MASH.
- Diagnostic AUROCs: desmosterol 0.79 (95% CI 0.66–0.92), phosphatidylcholine 0.80 (0.64–0.97), multi-lipid panel + ALT 0.91 (0.82–1.00).
Methodological Strengths
- Histology-verified MASLD spectrum with defined MASL vs MASH groups
- Comprehensive sterol and lipidomic profiling with logistic regression modeling
Limitations
- Single-center cohort with small sample size (n=86), cross-sectional design
- Potential selection bias and need for external validation; medication confounding addressed but residual bias possible
Future Directions: Prospective, multi-center external validation; threshold optimization; integration with clinical scores and imaging; utility for longitudinal monitoring and treatment response.
The accumulation of cholesterol and other lipids leading to hepatic lipotoxicity drives the progression of metabolic dysfunction-associated steatotic liver (MASL) to metabolic dysfunction-associated steatohepatitis (MASH), the advanced progressive stage of metabolic dysfunction-associated steatotic liver disease (MASLD). For MASH diagnosis, liver biopsy remains the reference standard, despite its invasiveness and limitations. Thus, this study aimed to find blood-derived lipid markers for MASH. We investigated serum samples from 86 patients with histologically characterized MASLD, spanning the disease spectrum (i.e. 62 patients with MASL (Fibrosis grade 0-4) and 24 patients with MASH (Fibrosis grade 2-4) with a balanced distribution of hepatocellular carcinoma) and analyzed sterol composition and lipidome. To identify the presence of MASH, logistic regression was performed on each candidate either in a single or combination with various clinical parameters. Serum levels of desmosterol and phosphatidylcholine are increased in patients with MASH compared to those with MASL. After exclusion of patients using lipid lowering drugs, an increase was also found in serum levels of cholesterol, cholesterol ester, lysophosphatidylcholine, lysophosphatidylethanolamine, phosphatidylethanolamine, and several individual lipid species. The ROC curve of each lipid candidate show the potential use of desmosterol, phosphatidylcholine, and a panel of lipid species in combination with alanine aminotransferase as potential diagnostic markers, characterized by a respective AUROC of 0.79 (95% CI 0.66-0.92), 0.80 (95% CI 0.64-0.97), and 0.91 (95% CI 0.82-1.00). Serum sterol and lipidome markers are characterized by strong AUROC results to distinguish with high accuracy MASH from MASL, potentially paving the way for future MASH biomarker development.
3. Alpha-Linolenic Acid and Mortality Among Adults With Type 2 Diabetes: Findings From Two National Cohorts.
Pooling NHANES and CHNS cohorts (n=9603; 75,535 person-years), higher dietary ALA intake was associated with lower all-cause and CVD mortality in adults with T2D. Adjusted pooled HRs for all-cause mortality across ALA tertiles were 1.00, 0.87, and 0.79, indicating a dose-response relationship.
Impact: This large, multinational cohort analysis links a specific dietary fatty acid (ALA) with lower mortality in T2D, informing nutritional strategies that complement pharmacotherapy.
Clinical Implications: Encouraging ALA-rich foods (e.g., flaxseed, walnuts, canola/soy oils) may be a pragmatic adjunct to reduce mortality risk in T2D, pending interventional confirmation.
Key Findings
- Combined analysis of NHANES and CHNS (n=9603) with 75,535 person-years and 2468 deaths.
- Adjusted pooled HRs for all-cause mortality across ALA tertiles: 1.00, 0.87 (0.76–0.99), 0.79 (0.67–0.94).
- Higher ALA intake associated with lower cardiovascular mortality as well.
- Dose-response pattern supports potential protective association.
Methodological Strengths
- Two independent national cohorts with large sample size and long follow-up
- Multivariable Cox models and pooled estimates demonstrating dose-response
Limitations
- Diet assessed via 24-h recalls subject to measurement error and day-to-day variability
- Observational design with potential residual confounding; no biomarker validation of ALA intake
Future Directions: Randomized dietary trials increasing ALA intake in T2D with cardiometabolic endpoints, and biomarker-based exposure assessment (e.g., erythrocyte fatty acids).
BACKGROUND: Dietary alpha-linolenic acid (ALA) regulates lipid metabolism and insulin sensitivity, but few studies have investigated the association between ALA and the risk of mortality among adults with type 2 diabetes (T2D). This study examines whether increasing dietary ALA intake contributes to the long-term survival of adults with T2D. METHODS: This cohort study included 9603 participants with T2D, including 7953 adults from the National Health and Nutrition Examination Survey (NHANES; 1999-2018) and 1650 adults from the China Health and Nutrition Survey (CHNS; 1997-2011). Dietary information was collected through 24-h dietary recalls. Cox proportional hazards regression was employed to estimate hazard ratios (HRs) and 95% CIs for mortality from all-cause and cardiovascular disease (CVD). RESULTS: During 75 535 person-years of follow-up, a total of 2468 deaths were documented. After multivariate adjustment, the pooled HRs (95% CIs) of all-cause mortality were 1.00, 0.87 (0.76-0.99), and 0.79 (0.67-0.94) across tertiles of ALA (p CONCLUSIONS: Higher dietary ALA intake was associated with a lower risk of all-cause and CVD mortality among adults with T2D.